by The global Dupuytrens disease market consists of products such as oral medications and non-steroidal anti-inflammatory drugs which are used for the management and treatment of symptoms associated with Dupuytren’s disease. Dupuytren’s disease also known as Dupuytren’s contracture is a condition characterized by deformity of fingers caused due to formation of collagen deposits under the skin of the palm which causes fingers to bend towards the palm. These products help in reducing inflammation and curvature of fingers thus providing relief to patients.
The Global Dupuytrens Disease Market is estimated to be valued at US$ 4.3 Bn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the global Dupuytren’s disease market are Endo International Plc, Bristol-Meyers Squibb Company, Spear Pharmaceuticals, GSK Plc., AstraZeneca, Hikma Pharmaceuticals Plc, LEO Pharma A/S, Fresenius Kabi AG, Bayer AG, Novartis AG, Pfizer Inc., Nantong Jinghua Pharmaceutical Co., Ltd., and Actiza Pharmaceutical Pvt. Ltd., 180 Life Sciences Corp. Key players are focused on developing new pharmaceutical formulations and devices for effective treatment of Global Dupuytrens Disease Market Trends.
The global Dupuytren’s disease market is majorly driven by increasing incidence rates of Dupuytren’s disease worldwide due to rising geriatric population. Aging is one of the major risk factors associated with Dupuytren’s disease. Moreover, changing lifestyle patterns and increasing prevalence of underlying conditions such as diabetes also contribute to the growth of Dupuytren’s disease cases.
The Dupuytren’s disease market is witnessing significant expansion in emerging economies of Asia Pacific, Middle East & Africa, and Latin America. Increasing healthcare expenditure and demand for advanced treatment options in developing countries will support the globalDupuytren’s disease market growth during the forecast period.
Market key trends
One of the key trends observed in the global Dupuytren’s disease market is the increasing emphasis on development of minimally invasive treatment procedures. Conditions like Dupuytren’s disease were traditionally managed through extensive surgical procedures which are associated with risks of complications and lengthy recovery periods. However, newer technologies for collagen breakdown using enzymes or radiations enable less invasive treatments with faster recovery and better outcomes. This trend is expected to positively influence the Dupuytren’s disease market over the coming years.
Porter’s Analysis
Threat of new entrants: New entrants will find it difficult to enter the market due to the need for strong distribution network and brand image.
Bargaining power of buyers: Buyers have low bargaining power due to lack of substitutes and high treatment costs associated with Dupuytren’s disease.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to availability of alternatives.
Threat of new substitutes: Potential substitutes are still in development phase and not approved commercially yet.
Competitive rivalry: Market dominated by big players due to high R&D investments needed.
The global Dupuytrens disease market is concentrated in North America due to high awareness levels and availability of advanced treatment options.The United States holds over 40% share of the total market value owing to presence of major players, robust reimbursement policies and large patient pool affected with Dupuytrens disease.
The Asia Pacific region is expected to be the fastest growing market during the forecast period. This is attributed to expanding healthcare infrastructure, growing medical tourism industry and increasing compulsions from patient support groups. Countries such as China, India and South Korea are anticipated to generate lucrative opportunities owing to rising healthcare spending levels and availability of cheaper treatment costs compared to developed nations.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
